SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI

BMC Cardiovascular Disorders

Research

Jian Li¹  Yulin Yang¹  Xiaolin Wang¹  Yongchao Wang¹  Hao Xu¹ 

[1] Department of Cardiology, the Affiliated Hospital of Qingdao University, Qingdao, China;

关键词: Abnormal blood glucose;    SGLT2 inhibitors;    Heart failure;    Statins;   

DOI  :  10.1186/s12872-023-03353-1

 received in 2023-01-26, accepted in 2023-06-16,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundTaking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function.Methods and resultsIn total, 333 non-diabetes patients with heart failure with reduced ejection fraction (HFrEF) after percutaneous coronary intervention (PCI) are included. The enrolled patients are divided into a matched group (n = 198) and an SGLT2 inhibitors group (n = 135). There are no statistical differences in general information between the two groups before treatment. After a mean follow-up time of 13 months, abnormal blood glucose levels are significantly higher in the matched group than in the SGLT2 inhibitors group (6.06 vs. 0.74%, P < 0.05). There are no statistically significant differences in the alanine aminotransferase (ALT), uric acid (UA), and estimated glomerular filtration (eGFR) levels between the two groups.ConclusionSGLT2 inhibitors play a significant protective role in reducing the risk of statins-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI, without increasing the burden on the heart, kidneys, and liver.

【 授权许可】

CC BY   
© The Author(s) 2023